Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
about
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestinguPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.Ethanol and Cancer Induce Similar Changes on Protein Expression Pattern of Human Fibroblast Cell.Bilateral ovarian carcinomas differ in the expression of metastasis-related genesTransferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.Histone deacetylase 2 (HDAC2) attenuates lipopolysaccharide (LPS)-induced inflammation by regulating PAI-1 expression.Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.Stress granules counteract senescence by sequestration of PAI-1.SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.
P2860
Q26801060-871A7EF7-7176-404A-B00B-6D0E6EA9DAB1Q30249137-2AC09878-EFCD-4935-9D05-D68E22D661FDQ35711136-6A17609B-1C0C-48CD-8A99-2934A3038B62Q36166157-F0B3705B-13F3-40D8-89FB-DACD043873CCQ37592091-06172519-C447-4FA5-866E-7C830676EF21Q37594079-FD83BCBC-BBCC-4E90-9AF6-45F79E17BA4CQ40343605-46B6F586-964F-4744-AB91-82E14503F195Q47126029-78151B2F-C73E-46C8-BB25-5F82519D9250Q47164118-1E3F9FF2-9593-4FA7-92A6-E77F0946E171Q47654382-AC6B2A5D-87ED-4BE0-85E0-27A125629A41Q51633169-2C1FDD6B-1519-4041-9105-1491792DE16BQ51758735-BBABA813-D7FB-497D-861B-85A00688FA5CQ52671448-893CA9D9-16D8-4F34-8E2E-3980F680BEB3
P2860
Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@ast
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@en
type
label
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@ast
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@en
prefLabel
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@ast
Inhibition of plasminogen acti ...... ic strategy in ovarian cancer.
@en
P2093
P2860
P50
P1476
Inhibition of plasminogen acti ...... tic strategy in ovarian cancer
@en
P2093
Masafumi Toyoshima
Masumi Ishibashi
Nobuo Yaegashi
Satsuki Mashiko
Takashi Dan
Toshinori Usui
Toshio Miyata
P2860
P304
P356
10.1080/15384047.2014.1001271
P577
2015-01-01T00:00:00Z